These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients. Ochoa-Hein E; Rajme-López S; Rodríguez-Aldama JC; Huertas-Jiménez MA; Chávez-Ríos AR; de Paz-García R; Haro-Osnaya A; González-Colín KK; González-González R; González-Lara MF; Ponce-de-León A; Galindo-Fraga A Am J Infect Control; 2021 Jul; 49(7):966-968. PubMed ID: 33352250 [TBL] [Abstract][Full Text] [Related]
28. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18. Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826 [TBL] [Abstract][Full Text] [Related]
29. Clostridioides difficile infection (CDI) during the COVID-19 pandemic. Spigaglia P Anaerobe; 2022 Apr; 74():102518. PubMed ID: 35063599 [TBL] [Abstract][Full Text] [Related]
30. Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases. Doll M; Marra AR; Apisarnthanarak A; Al-Maani AS; Abbas S; Rosenthal VD Int J Infect Dis; 2021 Jan; 102():188-195. PubMed ID: 33122100 [TBL] [Abstract][Full Text] [Related]
31. A multisite genomic epidemiology study of Miles-Jay A; Young VB; Pamer EG; Savidge TC; Kamboj M; Garey KW; Snitkin ES Microb Genom; 2021 Jun; 7(6):. PubMed ID: 34180789 [No Abstract] [Full Text] [Related]
33. Clostridioides (Clostridium) difficile isolated from paediatric patients in Western Australia 2019-2020. Perumalsamy S; Lim SC; Riley TV Pathology; 2022 Jun; 54(4):460-465. PubMed ID: 35125203 [TBL] [Abstract][Full Text] [Related]
34. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. Yakob L; Riley TV; Paterson DL; Clements AC BMC Infect Dis; 2013 Aug; 13():376. PubMed ID: 23947736 [TBL] [Abstract][Full Text] [Related]
35. Ribotyping of Clostridium difficile strains associated with nosocomial transmission and relapses in a Swedish County. Magnusson C; Wullt M; Löfgren S; Iveroth P; Akerlund T; Matussek A APMIS; 2013 Feb; 121(2):153-7. PubMed ID: 23030627 [TBL] [Abstract][Full Text] [Related]
36. Holding firm: Use of clinical correlation to improve Clostridioides difficile testing. Baghdadi J; Ganz DA; Chumpia M; Chang ET; de Peralta SS Am J Infect Control; 2020 Sep; 48(9):1104-1107. PubMed ID: 31862165 [TBL] [Abstract][Full Text] [Related]
37. Clostridioides (Clostridium) difficile-associated disease: Epidemiology among patients in a general hospital in Saudi Arabia. Al-Tawfiq JA; Rabaan AA; Bazzi AM; Raza S; Noureen M Am J Infect Control; 2020 Oct; 48(10):1152-1157. PubMed ID: 32122671 [TBL] [Abstract][Full Text] [Related]